Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ALKS 58.88 +0.20 (0.34%)
price chart
Cantor Fitzgerald Reaffirms Neutral Rating for Alkermes Plc (ALKS)
Alkermes Plc logo Cantor Fitzgerald reissued their neutral rating on shares of Alkermes Plc (NASDAQ:ALKS) in a report released on Thursday.
Alkermes plc (ALKS) to Present Data on Two-Month Dosing Option of ARISTADA at ...
Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA� (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress ...
Alkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript
Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today.
Alkermes plc (ALKS) Tops Q4 EPS by 11c  StreetInsider.com
Federated Investors Inc. PA Holds Stake in Alkermes PLC (ALKS)  The Cerbat Gem
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward
Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.
Why Alkermes PLC Skyrocketed Today
Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.
Credit Suisse Bullish on Alkermes Plc (ALKS) as It Takes a Leap FORWARD  Smarter Analyst
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint ...  StreetInsider.com
BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study ...
WASHINGTON, March 16 President Donald Trump's first budget outline, calling for a security-heavy realignment of federal spending, drew resistance on Thursday from his fellow Republicans in the U.S.
Alkermes Plc (ALKS) Shares Sold by Ladenburg Thalmann Financial Services Inc.
Alkermes Plc logo Ladenburg Thalmann Financial Services Inc. decreased its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 3.8% during the fourth quarter, Holdings Channel reports.
Alkermes plc (NASDAQ:ALKS) EPS Projection At $-0.035  Investor Newswire
Analyst Activity – Cowen and Company Reiterates Positive on Alkermes Plc ...
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas.
Alkermes Plc (ALKS) CMO Sells $624140.00 in Stock  BNB Daily (blog)
Norges Bank Buys Shares of 796569 Alkermes Plc (ALKS)  The Cerbat Gem
Investors Are Missing An Opportunity With Alkermes
We remain bullish on Alkermes (NASDAQ: ALKS) because of their substantial and growing revenue and their healthy pipeline of valuable assets.
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 37  Business Wire (press release)
Bullish Sweepers and Large Money Flow Witnessed in Alkermes plc (ALKS)  Highland Mirror
Analyst Activity – Cantor Fitzgerald Reiterates Hold on Alkermes Plc (NASDAQ:ALKS)
Today, Cantor Fitzgerald reiterated its Hold rating on Alkermes Plc (NASDAQ:ALKS) with a price target of $51.00. There are 3 hold ratings, 7 buy ratings on the stock.
The Alkermes Plc (ALKS) Receives “Hold” Rating from Cantor Fitzgerald  Petro Global News 24